GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Depending on the cause of your itchy skin, you may benefit from using more than one treatment. This may be especially needed in cases of chronic itching. For example, chronic itchiness related to ...

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...

Ipsen announces Bylvay data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS: Paris, France Tuesday, November 19, 2024, 11:00 H ...

No new safety findings were observed. The most common treatment-emergent adverse events (>10 percent) occurring more frequently in patients treated with Iqirvo than placebo in the double-blind period ...